A Reversal for Clementia Pharmaceuticals Inc. (CMTA) Is Not Near. The Stock Rises Again

March 14, 2018 - By Migdalia James

The stock of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) is a huge mover today! The stock increased 4.00% or $0.71 during the last trading session, reaching $18.46. About 105,987 shares traded or 32.29% up from the average. Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $585.51M company. It was reported on Mar, 14 by Barchart.com. We have $19.01 PT which if reached, will make NASDAQ:CMTA worth $17.57 million more.

Analysts await Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) to report earnings on May, 23. After $-0.37 actual EPS reported by Clementia Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -10.81 % EPS growth.

More notable recent Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) news were published by: Marketwatch.com which released: “Clementia Pharmaceuticals Inc.” on August 02, 2017, also Seekingalpha.com with their article: “Clementia Pharmaceuticals Readies $100 Million IPO” published on July 31, 2017, Globenewswire.com published: “Clementia Announces Presentation at the JP Morgan 36th Annual Healthcare …” on January 03, 2018. More interesting news about Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) were released by: Prnewswire.com and their article: “Clementia Pharmaceuticals to Host Symposium at the 8th International …” published on June 05, 2017 as well as Globenewswire.com‘s news article titled: “Clementia to Participate in Leerink Partners 7th Annual Global Healthcare …” with publication date: December 12, 2017.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $585.51 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: